Description: Ildong Pharmaceutical Co., Ltd. develops, manufactures, and sells pharmaceutical products in South Korea. The company offers active lactic acid bacterial and anti-diarrheal agents, antibiotics, antifungal and antiviral products, anti-histamine drugs, antineoplastic agents, and NSAIDs and analgesics, as well as vitamins, minerals, and nutrients; and drugs for blood circulation, cardiovascular and central nervous system, dental, endocrine and metabolic system, gastrointestinal system, respiratory system, topical preparation, and urogenital system applications. It also provides raw material drugs; health foods and foods; cosmetics; medical devices for scar treatment; and other drugs for treating thick wounds, osteoarthritis, periarthritis of shoulder, and artificial tears, as well as feminine cleanser products. In addition, the company manages licenses and provides contract manufacturing services. It also exports its products to approximately 20 countries worldwide. Ildong Pharmaceutical Co., Ltd. a strategic collaboration with Evotec SE to accelerate the development of various Ildong's proprietary projects through access to Evotec's INDiGO platform. The company was founded in 1941 and is headquartered in Seoul, South Korea.
Home Page: www.ildong.com
2, Baumoe-ro 27-gil
Seoul,
South Korea
Phone:
82 2 526 3114
Officers
| Name | Title |
|---|---|
| Yun Paul Woongsup | Chief Exec. Officer |
Exchange: KO
Country: KR : Korea (Republic of)
Currency: Korean Won (₩)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.601 |
| Price-to-Sales TTM: | 1.7985 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 1411 |